|Bid||2.35 x 1000|
|Ask||2.90 x 1800|
|Day's Range||2.42 - 2.52|
|52 Week Range||2.31 - 5.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
AzurRx BioPharma, Inc. (AZRX) provided an update regarding its Phase 2a trial for MS1819 for treatment of chronic pancreatic insufficiency (EPI) The April 23rd release identified consistent progress in the Phase 2a trial for MS1819 with respect to patient enrollment, safety and dose response. The trial is targeting 12 – 15 patients and is enrolling in France, Australia and New Zealand. Current screening and enrollment trends are on track for a 1H:18 study completion.
AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the pricing of an underwritten public offering of 4,160,000 shares of its common stock at an offering price of $2.50 per share. Oppenheimer & Co. Inc. is acting as sole underwriter for the offering. The closing of the offering is expected to occur on or about May 3, 2018, subject to the satisfaction of customary closing conditions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. AzurRx intends to use the net proceeds from the offering primarily for research and development expenses associated with AzurRx’s continuing clinical development and testing of MS1819, advancing its preclinical programs for AZX1103 and for other general corporate purposes and capital expenditures. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A preliminary prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC.
AzurRx BioPharma Inc. (AZRX) (“AzurRx” or the “Company”), today provided an update on the first nine treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis. The Company observed both clinical activity and a clear dose response, where the highest MS1819-SD dose cohort continued to show greater than 21% improvement in CFA (coefficient of fat absorption) in evaluable patients. Additionally, maximal absolute CFA response to treatment was up to 57%, with an inverse relationship to baseline CFA.
Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics AZX1103 shown to be safe and biologically active in a well-established ...
AzurRx BioPharma, Inc. (AZRX) filed their fiscal year 2017 10-K on March 16th providing a financial update on the company’s performance. The filing caps off a year that saw progression of the Phase IIa trial for MS 1819 for treatment of exocrine pancreatic insufficiency (EPI), new patent protection filings and new personnel and board additions. In 2018, the company received approval for a clinical site in France and continued to add new patients.
CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( smm.global ): Research Report Here About AzurRx, Biopharma, ...
BROOKLYN, N.Y., Feb. 28, 2018-- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will ...
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
In this analysis, my focus will be on developing a perspective on AzurRx BioPharma Inc’s (NASDAQ:AZRX) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...
AzurRx BioPharma Inc (NASDAQ:AZRX), a USD$40.21M small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need forRead More...
By John Vandermosten, CFA NASDAQ:AZRX AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced an update to their Phase IIa Trial outcomes for MS1819. The company announced interim results for the first six patients ...
The Digital Issue of the Fall 2017 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / September 5, 2017 / ...